STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
NeuroVive (STO:NVP)
Business operations
Important events July-September 2016
• NeuroVive completed a 10 percent partial acquisition of its business partner, Isomerase Therapeutics
• NeuroVive received a request to terminate the Company’s license agreement with Arbutus Biopharma
